Advertisement

Metabolic Syndrome and Sexual (Dys)function

      ABSTRACT

      Introduction

      The general worldwide increase in metabolic syndrome (MS) among most populations may result in more individuals with sexual dysfunction.

      Aim

      To provide an update on clinical and experimental evidence regarding sexual dysfunction in patients with MS from both sexes and treatment modalities.

      Methods

      A comprehensive literature review was performed using MEDLINE with the MeSH terms and keywords for “metabolic syndrome,”“obesity,”“female sexual dysfunction,”“erectile dysfunction,”“androgen deficiency,”“weight loss,” and “bariatric surgery.”

      Main Outcome Measures

      To examine the data relating to sexual function in both men and women with MS, its relationship and the impact of treatment.

      Results

      The MS is strongly correlated with erectile dysfunction, hypogonadism (predictors of future development of MS), and female sexual dysfunction. Few studies have been addressed in the treatment of these dysfunctions in the special setting of MS, other than the observational effects on sexual function of individual risk factors correction. This can be a result of their understudied etiopathogeny. Nonsurgical weight loss has been shown to improve sexual function (with the mainstay on sedentarism prevention), whereas the efficacy of bariatric surgery in this respect, which has been suggested by some preliminary evidence, needs to be further confirmed by adequate clinical trials.

      Conclusion

      As the global incidence of MS increases, more individuals may experience sexual dysfunction and a systematic evaluation should be emphasized in this patient population, in order to identify those who are in need of intervention. Borges R, Temido P, Sousa L, Azinhais P, Conceição P, Pereira B, Leão R, Retroz E, Brandão Á, Cristo L, and Sobral F. Metabolic syndrome and sexual (dys)function.

      Keywords

      To read this article in full you will need to make a payment
      ISSM Member Login
      Login with your ISSM username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Caballero B.
        The global epidemic of obesity: An overview.
        Epidemiol Rev. 2007; 29: 1-5
        • WHO Consultation on Obesity
        Obesity: Preventing and managing the global epidemic. Report of a WHO consultation.
        World Health Organ Tech Rep Ser. 2000; 894: i-xii
      1. Ruhm CJ. Current and future prevalence of obesity and severe obesity in the United States. NBER Working Paper No 13181. 2007.

        • Muller A.
        • Mulhall J.P.
        Cardiovascular disease, metabolic syndrome and erectile dysfunction.
        Curr Opin Urol. 2006; 16: 435-443
        • Corona G.
        • Mannucci E.
        • Forti G.
        • Maggi M.
        Hypogonadism ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases.
        Int J Androl. 2009;
        • Balkau B.
        • Charles M.A.
        Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).
        Diabet Med. 1999; 16: 442-443
        • Einhorn D.
        • Reaven G.M.
        • Cobin R.H.
        • Ford E.
        • Ganda O.P.
        • Handelsman Y.
        • Hellman R.
        • Jellinger P.S.
        • Kendall D.
        • Krauss R.M.
        • Neufeld N.D.
        • Petak S.M.
        • Rodbard H.W.
        • Seibel J.A.
        • Smith D.A.
        • Wilson P.W.
        American College of Endocrinology position statement on the insulin resistance syndrome.
        Endocr Pract. 2003; 9: 237-252
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Adams R.J.
        • Appleton S.
        • Wilson D.H.
        • Taylor A.W.
        • Dal Grande E.
        • Chittleborough C.
        • Gill T.
        • Ruffin R.
        Population comparison of two clinical approaches to the metabolic syndrome: Implications of the new International Diabetes Federation consensus definition.
        Diabetes Care. 2005; 28: 2777-2779
        • Mannucci E.
        • Monami M.
        • Bardini G.
        • Ognibene A.
        • Rotella C.M.
        National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: Results from the FIBAR Study.
        J Endocrinol Invest. 2007; 30: 925-930
        • Monami M.
        • Lambertucci L.
        • Ungar A.
        • Pieri M.
        • Masotti G.
        • Marchionni N.
        • Mannucci E.
        Is the third component of metabolic syndrome really predictive of outcomes in type 2 diabetic patients?.
        Diabetes Care. 2006; 29: 2515-2517
        • Corona G.
        • Mannucci E.
        • Petrone L.
        • Schulman C.
        • Balercia G.
        • Fisher A.D.
        • Chiarini V.
        • Forti G.
        • Maggi M.
        A comparison of NCEP‐ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome‐associated sexual dysfunction.
        J Sex Med. 2007; 4: 789-796
        • Hydrie M.Z.
        • Shera A.S.
        • Fawwad A.
        • Basit A.
        • Hussain A.
        Prevalence of metabolic syndrome in urban Pakistan (Karachi): Comparison of newly proposed International Diabetes Federation and Modified Adult Treatment Panel III criteria.
        Metab Syndr Relat Disord. 2009; 7: 119-124
        • Koutsovasilis A.
        • Protopsaltis J.
        • Triposkiadis F.
        • Kokkoris S.
        • Milionis H.J.
        • Zairis M.N.
        • Skoularigis J.
        • Koukoulis G.
        • Korantzopoulos P.
        • Melidonis A.
        • Foussas S.G.
        Comparative performance of three metabolic syndrome definitions in the prediction of acute coronary syndrome.
        Intern Med. 2009; 48: 179-187
        • Luk A.O.
        • Ma R.C.
        • So W.Y.
        • Yang X.L.
        • Kong A.P.
        • Ozaki R.
        • Ko G.T.
        • Chow C.C.
        • Cockram C.S.
        • Chan J.C.
        • Tong P.C.
        The NCEP‐ATPIII but not the IDF criteria for the metabolic syndrome identify type 2 diabetic patients at increased risk of chronic kidney disease.
        Diabet Med. 2008; 25: 1419-1425
        • Villegas R.
        • Xiang Y.B.
        • Yang G.
        • Cai Q.
        • Fazio S.
        • Linton M.F.
        • Elasy T.
        • Xu W.H.
        • Li H.
        • Cai H.
        • Gao Y.T.
        • Zheng W.
        • Shu X.O.
        Prevalence and determinants of metabolic syndrome according to three definitions in middle‐aged Chinese men.
        Metab Syndr Relat Disord. 2009; 7: 37-45
        • Kelliny C.
        • William J.
        • Riesen W.
        • Paccaud F.
        • Bovet P.
        Metabolic syndrome according to different definitions in a rapidly developing country of the African region.
        Cardiovasc Diabetol. 2008; 7: 27
        • Sarmiento Mendez L.M.
        • Roca‐Cusachs Coll A.
        • Arroyo Diaz J.A.
        • Benet Gusta M.T.
        • Sole Villa M.J.
        • Franco Peral M.
        [Comparison of the definitions of the metabolic syndrome according to ATP III and IDF].
        Rev Clin Esp. 2008; 208: 333-338
        • Ford E.S.
        • Giles W.H.
        • Dietz W.H.
        Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey.
        JAMA. 2002; 287: 356-359
        • Hu G.
        • Qiao Q.
        • Tuomilehto J.
        • Balkau B.
        • Borch‐Johnsen K.
        • Pyorala K.
        Prevalence of the metabolic syndrome and its relation to all‐cause and cardiovascular mortality in nondiabetic European men and women.
        Arch Intern Med. 2004; 164: 1066-1076
        • Sattar N.
        • Gaw A.
        • Scherbakova O.
        • Ford I.
        • O'Reilly D.S.
        • Haffner S.M.
        • Isles C.
        • Macfarlane P.W.
        • Packard C.J.
        • Cobbe S.M.
        • Shepherd J.
        Metabolic syndrome with and without C‐reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
        Circulation. 2003; 108: 414-419
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • Stern M.
        The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2005; 28: 2289-2304
        • Grundy S.M.
        Metabolic syndrome: A multiplex cardiovascular risk factor.
        J Clin Endocrinol Metab. 2007; 92: 399-404
        • Basson R.
        Women's sexual dysfunction: Revised and expanded definitions.
        CMAJ. 2005; 172: 1327-1333
        • Frank E.
        • Anderson C.
        • Rubinstein D.
        Frequency of sexual dysfunction in “normal” couples.
        New Engl J Med. 1978; 299: 111-115
        • Laumann E.O.
        • Paik A.
        • Rosen R.C.
        Sexual dysfunction in the United States: Prevalence and predictors.
        JAMA. 1999; 281: 537-544
        • Hayes R.D.
        • Dennerstein L.
        • Bennett C.M.
        • Fairley C.K.
        What is the “true” prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact?.
        J Sex Med. 2008; 5: 777-787
        • Raina R.
        • Pahlajani G.
        • Khan S.
        • Gupta S.
        • Agarwal A.
        • Zippe C.D.
        Female sexual dysfunction: Classification, pathophysiology, and management.
        Fertil Steril. 2007; 88: 1273-1284
        • Kirchengast S.
        • Hartmann B.
        • Gruber D.
        • Huber J.
        Decreased sexual interest and its relationship to body build in postmenopausal women.
        Maturitas. 1996; 23: 63-71
        • Adolfsson B.
        • Elofsson S.
        • Rössner S.
        • Undén A.L.
        Are sexual dissatisfaction ad sexual abuse associated with obesity? A population‐based study.
        Obes Res. 2004; 12: 1702-1709
        • Esposito K.
        • Giugliano F.
        • Ciotola M.
        • De Sio M.
        • D'Armiento M.
        • Giugliano D.
        Obesity and sexual dysfunction, male and female.
        Int J Impot Res. 2008; 20: 358-365
        • Ponholzer A.
        • Temml C.
        • Rauchenwald M.
        • Marszalek M.
        • Madersbacher S.
        Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?.
        Int J Impot Res. 2008; 20: 100-104
        • Kaneshiro B.
        • Jensen J.T.
        • Carlson N.E.
        • Harvey S.M.
        • Nichols M.D.
        • Edelman A.B.
        Body mass index and sexual behavior.
        Obstet Gynecol. 2008; 112: 586-592
        • Holt V.L.
        • Cushing‐Haugen K.L.
        • Daling J.R.
        Body weight and risk of oral contraceptive failure.
        Obstet Gynecol. 2002; 99: 820-827
        • Holt V.L.
        • Scholes D.
        • Wicklund K.G.
        • Cushing‐Haugen K.L.
        • Daling J.R.
        Body mass index, weight, and oral contraceptive failure risk.
        Obstet Gynecol. 2005; 105: 46-52
        • Gesink Law D.C.
        • Maclehose R.F.
        • Longnecker M.P.
        Obesity and time to pregnancy.
        Human Reprod. 2007; 22: 414-420
        • Garcia S.
        • Moreno S.
        • Aponte H.
        Prevalence of sexual dysfunction in female outpatients and personnel at a Colombian hospital: Correlation with hormonal profile.
        J Sex Med. 2008; 5: 1208-1213
        • Arlt W.
        Androgen therapy in women.
        Eur J Endocrinol. 2006; 154: 1-11
        • Bachmann G.
        • Bancroft J.
        • Braunstein G.
        • Burger H.
        • Davis S.
        • Dennerstein L.
        • Goldstein I.
        • Guay A.
        • Leiblum S.
        • Lobo R.
        • Notelovitz M.
        • Rosen R.
        • Sarrel P.
        • Sherwin B.
        • Simon J.
        • Simpson E.
        • Shifren J.
        • Spark R.
        • Traish A.
        • Princeton
        Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment.
        Fertil Steril. 2002; 77: 660-665
        • Goldstein I.
        • Traish A.
        • Kim N.
        • Munarriz R.
        The role of sex steroid hormones in female sexual function and dysfunction.
        Clin Obstet Gynecol. 2004; 47: 471-484
        • Rivera‐Woll L.M.
        • Papalia M.
        • Davis S.R.
        • Burger H.G.
        Androgen insufficiency in women: Diagnostic and therapeutic implications.
        Hum Reprod Update. 2004; 10: 421-432
        • Miller E.L.
        • Mitchell A.
        Metabolic syndrome: Screening, diagnosis, and management.
        J Midwifery Womens Health. 2006; 51: 141-151
        • Dokras A.
        • Bochner M.
        • Hollinrake E.
        • Markham S.
        • Vanvoorhis B.
        • Jagasia D.H.
        Screening women with polycystic ovary syndrome for metabolic syndrome.
        Obstet Gynecol. 2005; 106: 131-137
        • Apridonidze T.
        • Essah P.A.
        • Iuorno M.J.
        • Nestler J.E.
        Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2005; 90: 1929-1935
        • Skrzypulec V.
        • Nowosielski K.
        • Drosdzol A.
        • Kowalaczyk R.
        Sexual dysfunctions in selected endocrinopathies.
        Endokrynol Pol. 2005; 56: 964-969
        • Melin I.
        • Falconer C.
        • Rossner S.
        • Altman D.
        Sexual function in obese women: Impact of lower urinary tract dysfunction.
        Int J Obes (2005). 2008; 32: 1312-1318
        • McIntyre R.S.
        • Rasgon N.L.
        • Kemp D.E.
        • Nguyen H.T.
        • Law C.W.
        • Taylor V.H.
        • Woldeyohannes H.O.
        • Alsuwaidan M.T.
        • Soczynska J.K.
        • Kim B.
        • Lourenco M.T.
        • Kahn L.S.
        • Goldstein B.I.
        Metabolic syndrome and major depressive disorder: Co‐occurrence and pathophysiologic overlap.
        Curr Diab Rep. 2009; 9: 51-59
        • Morgan C.D.
        • Wiederman M.W.
        • Pryor T.L.
        Sexual functioning and attitudes of eating‐disordered women: A follow‐up study.
        J Sex Marital Ther. 1995; 21: 67-77
        • Patrick L.
        Eating disorders: A review of the literature with emphasis on medical complications and clinical nutrition.
        Altern Med Rev. 2002; 7: 184-202
        • Roehrig M.
        • Masheb R.M.
        • White M.A.
        • Grilo C.M.
        The metabolic syndrome and behavioral correlates in obese patients with binge eating disorder.
        Obesity (Silver Spring). 2009; 17: 481-486
        • Bhasin S.
        • Enzlin P.
        • Coviello A.
        • Basson R.
        Sexual dysfunction in men and women with endocrine disorders.
        Lancet. 2007; 369: 597-611
        • Basson R.
        Female sexual response: The role of drugs in the management of sexual dysfunction.
        Obstet Gynecol. 2001; 98: 350-353
        • Montgomery J.C.
        • Appleby L.
        • Brincat M.
        • Versi E.
        • Tapp A.
        • Fenwick P.B.
        • Studd J.W.
        Effect of oestrogen and testosterone implants on psychological disorders in the climacteric.
        Lancet. 1987; 1: 297-299
        • Burkman R.T.
        • Collins J.A.
        • Greene R.A.
        Current perspectives on benefits and risks of hormone replacement therapy.
        Am J Obstet Gynecol. 2001; 185: S13-S23
        • Cardozo L.
        • Bachmann G.
        • McClish D.
        • Fonda D.
        • Birgerson L.
        Meta‐analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee.
        Obstet Gynecol. 1998; 92: 722-727
        • Collins A.
        • Landgren B.M.
        Reproductive health, use of estrogen and experience of symptoms in perimenopausal women: A population‐based study.
        Maturitas. 1994; 20: 101-111
        • Basson R.
        • McInnes R.
        • Smith M.D.
        • Hodgson G.
        • Koppiker N.
        Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
        J Womens Health Gen Based Med. 2002; 11: 367-377
        • Berman J.R.
        • Berman L.A.
        • Lin H.
        • Flaherty E.
        • Lahey N.
        • Goldstein I.
        • Cantey‐Kiser J.
        Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder.
        J Sex Marital Ther. 2001; 27: 411-420
        • Wilson S.K.
        • Delk 2nd, J.R.
        • Billups K.L.
        Treating symptoms of female sexual arousal disorder with the Eros‐Clitoral Therapy Device.
        J Gend Specif Med. 2001; 4: 54-58
        • Pauls R.N.
        • Marinkovic S.P.
        • Silva W.A.
        • Rooney C.M.
        • Kleeman S.D.
        • Karram M.M.
        Effects of sacral neuromodulation on female sexual function.
        Int Urogynecol J Pelvic Floor Dysfunct. 2007; 18: 391-395
        • Salpeter S.R.
        • Walsh J.M.
        • Ormiston T.M.
        • Greyber E.
        • Buckley N.S.
        • Salpeter E.E.
        Meta‐analysis effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women.
        Diabetes Obes Metab. 2006; 8: 538-554
        • Sowers M.
        • Zheng H.
        • Tomey K.
        • Karvonen‐Gutierrez C.
        • Jannausch M.
        • Li X.
        • Yosef M.
        • Symons J.
        Changes in body composition in women over six years at midlife: Ovarian and chronological aging.
        J Clin Endocrinol Metab. 2007; 92: 895-901
        • Tchernof A.
        • Calles‐Escandon J.
        • Sites C.K.
        • Poehlman E.T.
        Menopause, central body fatness, and insulin resistance: Effects of hormone‐replacement therapy.
        Coron Artery Dis. 1998; 9: 503-511
        • Lobo R.A.
        Metabolic syndrome after menopause and the role of hormones.
        Maturitas. 2008; 60: 10-18
        • Gaspard U.
        Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women.
        Maturitas. 2009;
      2. Proceedings of the 3rd European Consensus Development Conference on Sex Steroids and Cardiovascular diseases, 6–9 November 2002.
        Maturitas. 2004; 47: 243-318
        • Sites C.K.
        • L'Hommedieu G.D.
        • Toth M.J.
        • Brochu M.
        • Cooper B.C.
        • Fairhurst P.A.
        The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: A randomized, double‐blind, placebo‐controlled trial.
        J Clin Endocrinol Metab. 2005; 90: 2701-2707
        • Tanko L.B.
        • Christiansen C.
        Effects of 17beta‐oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
        J Intern Med. 2005; 258: 544-553
        • Corona G.
        • Mannucci E.
        • Schulman C.
        • Petrone L.
        • Mansani R.
        • Cilotti A.
        • Balercia G.
        • Chiarini V.
        • Forti G.
        • Maggi M.
        Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction.
        Eur Urol. 2006; 50: 595-604
        • Gunduz M.I.
        • Gumus B.H.
        • Sekuri C.
        Relationship between metabolic syndrome and erectile dysfunction.
        Asian J Androl. 2004; 6: 355-358
        • Esposito K.
        • Giugliano F.
        • Martedi E.
        • Feola G.
        • Marfella R.
        • D'Armiento M.
        • Giugliano D.
        High proportions of erectile dysfunction in men with the metabolic syndrome.
        Diabetes Care. 2005; 28: 1201-1203
        • Demir T.
        • Demir O.
        • Kefi A.
        • Comlekci A.
        • Yesil S.
        • Esen A.
        Prevalence of erectile dysfunction in patients with metabolic syndrome.
        Int J Urol. 2006; 13: 385-388
        • Kupelian V.
        • Shabsigh R.
        • Araujo A.B.
        • O'Donnell A.B.
        • McKinlay J.B.
        Erectile dysfunction as a predictor of the metabolic syndrome in aging men: Results from the Massachusetts Male Aging Study.
        J Urol. 2006; 176: 222-226
        • Grover S.A.
        • Lowensteyn I.
        • Kaouache M.
        • Marchand S.
        • Coupal L.
        • DeCarolis E.
        • Defoy Zoccoli J.
        The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease.
        Arch Intern Med. 2006; 166: 213-219
        • Heidler S.
        • Temml C.
        • Broessner C.
        • Mock K.
        • Rauchenwald M.
        • Madersbacher S.
        • Ponholzer A.
        Is the metabolic syndrome an independent risk factor for erectile dysfunction?.
        J Urol. 2007; 177: 651-654
        • Bal K.
        • Oder M.
        • Sahin A.S.
        • Karataş C.T.
        • Demir O.
        • Can E.
        • Gümüş B.H.
        • Ozer K.
        • Sahin O.
        • Esen A.A.
        Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: Metabolic backgrounds of erectile dysfunction.
        Urology. 2007; 69: 350-356
        • Yeh H.C.
        • Wang C.J.
        • Lee Y.C.
        • Hsiao H.L.
        • Wu W.J.
        • Chou Y.H.
        • Huang C.H.
        Association among metabolic syndrome, testosterone level and severity of erectile dysfunction.
        Kaohsiung J Med Sci. 2008; 24: 240-247
        • Bansal T.C.
        • Guay A.T.
        • Jacobson J.
        • Woods B.O.
        • Nesto R.W.
        Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction.
        J Sex Med. 2005; 2: 96-103
        • Yassin A.A.
        • Saad F.
        • Gooren L.J.
        Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone.
        Andrologia. 2008; 40: 259-264
        • Fedele D.
        • Coscelli C.
        • Santeusanio F.
        • Bortolotti A.
        • Chatenoud L.
        • Colli E.
        • Landoni M.
        • Parazzini F.
        Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici.
        Diabetes Care. 1998; 21: 1973-1977
        • Fedele D.
        • Coscelli C.
        • Cucinotta D.
        • Forti G.
        • Santeusanio F.
        • Viaggi S.
        • Fiori G.
        • Velonà T.
        • Lavezzari M.
        • Diade Study Group
        Incidence of erectile dysfunction in Italian men with diabetes.
        J Urol. 2001; 166: 1368-1371
        • Fedele D.
        Therapy insight: Sexual and bladder dysfunction associated with diabetes mellitus.
        Nat Clin Pract Urol. 2005; 2: 282-290
        • Shabsigh R.
        • Arver S.
        • Channer K.S.
        • Eardley I.
        • Fabbri A.
        • Gooren L.
        • Heufelder A.
        • Jones H.
        • Meryn S.
        • Zitzmann M.
        The triad of erectile dysfunction, hypogonadism and the metabolic syndrome.
        Int J Clin Pract. 2008; 62: 791-798
        • Bonetti P.O.
        • Lerman L.O.
        • Lerman A.
        Endothelial dysfunction: A marker of atherosclerotic risk.
        Arterioscler Thromb Vasc Biol. 2003; 23: 168-175
        • Blumentals W.A.
        • Gomez‐Caminero A.
        • Joo S.
        • Vannappagari V.
        Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study.
        Int J Impot Res. 2004; 16: 350-353
        • Fonseca V.
        • Jawa A.
        Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments?.
        Am J Cardiol. 2005; 96: 13M-18M
        • Stehouwer C.D.
        • Henry R.M.
        • Ferreira I.
        Arterial stiffness in diabetes and the metabolic syndrome: A pathway to cardiovascular disease.
        Diabetologia. 2008; 51: 527-539
        • Esposito K.
        • Giugliano D.
        Obesity, the metabolic syndrome, and sexual dysfunction.
        Int J Impot Res. 2005; 17: 391-398
        • Corona G.
        • Razzoli E.
        • Forti G.
        • Maggi M.
        The use of phosphodiesterase 5 inhibitors with concomitant medications.
        J Endocrinol Invest. 2008; 31: 799-808
        • Jackson G.
        The importance of risk factor reduction in erectile dysfunction.
        Curr Urol Rep. 2007; 8: 463-466
        • Kloner R.A.
        Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: Focus on alpha‐blocker interactions.
        Am J Cardiol. 2005; 96: 42M-46M
        • Bank A.J.
        • Kelly A.S.
        • Kaiser D.R.
        • Crawford W.W.
        • Waxman B.
        • Schow D.A.
        • Billups K.L.
        The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
        Vasc Med. 2006; 11: 251-257
        • Toblli J.E.
        • Cao G.
        • Lombrana A.
        • Rivero M.
        Functional and morphological improvement in erectile tissue of hypertensive rats by long‐term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
        J Sex Med. 2007; 4: 1291-1303
        • Chen Y.
        • Li S.X.
        • Yao L.S.
        • Wang R.
        • Dai Y.T.
        Valsartan treatment reverses erectile dysfunction in diabetic rats.
        Int J Impot Res. 2007; 19: 366-370
        • Dusing R.
        Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men.
        Blood Press. 2003; 2: 29-34
        • Baumhakel M.
        • Schlimmer N.
        • Bohm M.
        Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.
        Int J Impot Res. 2008;
        • Rizvi K.
        • Hampson J.P.
        • Harvey J.N.
        Do lipid‐lowering drugs cause erectile dysfunction? A systematic review.
        Fam Prac. 2002; 19: 95-98
        • Fibbi B.
        • Morelli A.
        • Marini M.
        • Zhang X.H.
        • Mancina R.
        • Vignozzi L.
        • Filippi S.
        • Chavalmane A.
        • Silvestrini E.
        • Colli E.
        • Adorini L.
        • Vannelli G.B.
        • Maggi M.
        Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway.
        J Androl. 2008; 29: 70-84
        • Herrmann H.C.
        • Levine L.A.
        • Macaluso Jr, J.
        • Walsh M.
        • Bradbury D.
        • Schwartz S.
        • Mohler 3rd, E.R.
        • Kimmel S.E.
        Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results.
        J Sex Med. 2006; 3: 303-308
        • Hong S.K.
        • Han B.K.
        • Jeong S.J.
        • Byun S.S.
        • Lee S.E.
        Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
        J Urol. 2007; 178: 613-616
        • Miner M.
        • Billups K.L.
        Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type‐5 inhibitors and statins.
        J Sex Med. 2008; 5: 1066-1078
        • Castro M.M.
        • Rizzi E.
        • Rascado R.R.
        • Nagassaki S.
        • Bendhack L.M.
        • Tanus‐Santos J.E.
        Atorvastatin enhances sildenafil‐induced vasodilation through nitric oxide‐mediated mechanisms.
        Eur J Pharmacol. 2004; 498: 189-194
        • Ferrer E.
        • Moral M.A.
        • Bozzo J.
        The role of statins in erectile dysfunction.
        Drugs Today (Barc). 2007; 43: 55-59
        • Harman S.M.
        • Metter E.J.
        • Tobin J.D.
        • Pearson J.
        • Blackman M.R.
        Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.
        J Clin Endocrinol Metab. 2001; 86: 724-731
        • Kaplan S.A.
        • Meehan A.G.
        • Shah A.
        The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?.
        J Urol. 2006; 176: 1524-1527
        • Laaksonen D.E.
        • Niskanen L.
        • Punnonen K.
        • Nyyssönen K.
        • Tuomainen T.P.
        • Salonen R.
        • Rauramaa R.
        • Salonen J.T.
        Sex hormones, inflammation and the metabolic syndrome: A population‐based study.
        Eur J Endocrinol. 2003; 149: 601-608
        • Kupelian V.
        • Page S.T.
        • Araujo A.B.
        • Travison T.G.
        • Bremner W.J.
        • McKinlay J.B.
        Low sex hormone‐binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.
        J Clin Endocrinol Metab. 2006; 91: 843-850
        • Chubb S.A.
        • Hyde Z.
        • Almeida O.P.
        • Flicker L.
        • Norman P.E.
        • Jamrozik K.
        • Hankey G.J.
        • Yeap B.B.
        Lower sex hormone‐binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: The Health in Men Study.
        Eur J Endocrinol. 2008; 158: 785-792
        • Larsen S.H.
        • Wagner G.
        • Heitmann B.L.
        Sexual function and obesity.
        Int J Obesity (2005). 2007; 31: 1189-1198
        • Zumoff B.
        Hormonal abnormalities in obesity.
        Acta Med Scand Suppl. 1988; 723: 153-160
        • Lima N.
        • Cavaliere H.
        • Knobel M.
        • Halpern A.
        • Medeiros‐Neto G.
        Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat.
        Int J Obes Relat Metab Disord. 2000; 24: 1433-1437
        • Vermeulen A.
        • Kaufman J.M.
        • Deslypere J.P.
        • Thomas G.
        Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men.
        J Clin Endocrinol Metab. 1993; 76: 1140-1146
        • Loves S.
        • Ruinemans‐Koerts J.
        • De Boer H.
        Letrozole once a week normalizes serum testosterone in obesity‐related male hypogonadism.
        Eur J Endocrinol. 2008; 158: 741-747
        • Isidori A.M.
        • Caprio M.
        • Strollo F.
        • Moretti C.
        • Frajese G.
        • Isidori A.
        • Fabbri A.
        Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels.
        J Clin Endocrinol Metab. 1999; 84: 3673-3680
        • Dusserre E.
        • Moulin P.
        • Vidal H.
        Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues.
        Biochim Biophys Acta. 2000; 1500: 88-96
        • Pitteloud N.
        • Hardin M.
        • Dwyer A.A.
        • Valassi E.
        • Yialamas M.
        • Elahi D.
        • Hayes F.J.
        Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.
        J Clin Endocrinol Metab. 2005; 90: 2636-2641
        • Burcelin R.
        • Thorens B.
        • Glauser M.
        • Gaillard R.C.
        • Pralong F.P.
        Gonadotropin‐releasing hormone secretion from hypothalamic neurons: Stimulation by insulin and potentiation by leptin.
        Endocrinology. 2003; 144: 4484-4491
        • Bruning J.C.
        • Gautam D.
        • Burks D.J.
        • Gillette J.
        • Schubert M.
        • Orban P.C.
        • Klein R.
        • Krone W.
        • Müller‐Wieland D.
        • Kahn C.R.
        Role of brain insulin receptor in control of body weight and reproduction.
        Science. 2000; 289: 2122-2125
        • Boyanov M.A.
        • Boneva Z.
        • Christov V.G.
        Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.
        Aging Male. 2003; 6: 1-7
        • Kapoor D.
        • Goodwin E.
        • Channer K.S.
        • Jones T.H.
        Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
        Eur J Endocrinol. 2006; 154: 899-906
        • Marin P.
        • Arver S.
        Androgens and abdominal obesity.
        Baillieres Clin Endocrinol Metab. 1998; 12: 441-451
        • Kapoor D.
        • Clarke S.
        • Channer K.S.
        • Jones T.H.
        Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes.
        Int J Androl. 2007; 30: 500-507
        • Wang C.
        • Nieschlag E.
        • Swerdloff R.
        • Behre H.M.
        • Hellstrom W.J.
        • Gooren L.J.
        • Kaufman J.M.
        • Legros J.J.
        • Lunenfeld B.
        • Morales A.
        • Morley J.E.
        • Schulman C.
        • Thompson I.M.
        • Weidner W.
        • Wu F.C.
        ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late‐onset hypogonadism in males.
        Int J Impot Res. 2009; 21: 1-8
        • Yassin A.A.
        • Saad F.
        Testosterone and erectile dysfunction.
        Int J Androl. 2008; 29: 593-604
        • Morelli A.
        • Filippi S.
        • Mancina R.
        • Luconi M.
        • Vignozzi L.
        • Marini M.
        • Orlando C.
        • Vannelli G.B.
        • Aversa A.
        • Natali A.
        • Forti G.
        • Giorgi M.
        • Jannini E.A.
        • Ledda F.
        • Maggi M.
        Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.
        Endocrinology. 2004; 145: 2253-2263
        • Traish A.M.
        • Park K.
        • Dhir V.
        • Kim N.N.
        • Moreland R.B.
        • Goldstein I.
        Effects of castration and androgen replacement on erectile function in a rabbit model.
        Endocrinology. 1999; 140: 1861-1868
        • Aversa A.
        • Isidori A.M.
        • Spera G.
        • Lenzi A.
        • Fabbri A.
        Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction.
        Clin Endocrinol (Oxf). 2003; 58: 632-638
        • Kalinchenko S.Y.
        • Kozlov G.I.
        • Gontcharov N.P.
        • Katsiya G.V.
        Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone.
        Aging Male. 2003; 6: 94-99
        • Shabsigh R.
        Testosterone therapy in erectile dysfunction.
        Aging Male. 2004; 7: 312-318
        • Yassin A.A.
        • Saad F.
        Treatment of sexual dysfunction of hypogonadal patients with long‐acting testosterone undecanoate (Nebido).
        World J Urol. 2006; 24: 639-644
        • Kaukua J.
        • Pekkarinen T.
        • Sane T.
        • Mustajoki P.
        Sex hormones and sexual function in obese men losing weight.
        Obes Res. 2003; 11: 689-694
        • Niskanen L.
        • Laaksonen D.E.
        • Punnonen K.
        • Mustajoki P.
        • Kaukua J.
        • Rissanen A.
        Changes in sex hormone‐binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome.
        Diabetes Obes Metab. 2004; 6: 208-215
        • Droupy S.
        • Descazeaud A.
        Syndrome métabolique et dysfonctions sexuelles.
        Sexologies. 2007; 16: S6-S9
        • Kinzl J.F.
        • Trefalt E.
        • Fiala M.
        • Hotter A.
        • Biebl W.
        • Aigner F.
        Partnership, sexuality, and sexual disorders in morbidly obese women: Consequences of weight loss after gastric banding.
        Obes Surg. 2001; 11: 455-458
        • Hawley J.A.
        Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance.
        Diabetes Metab Res Rev. 2004; 20: 383-393
        • Hawley J.A.
        • Lessard S.J.
        Exercise training‐induced improvements in insulin action.
        Acta physiol (Oxf). 2008; 192: 127-135
        • Esposito K.
        • Ciotola M.
        • Giugliano F.
        • Schisano B.
        • Autorino R.
        • Iuliano S.
        • Vietri M.T.
        • Cioffi M.
        • De Sio M.
        • Giugliano D.
        Mediterranean diet improves sexual function in women with the metabolic syndrome.
        Int J Impot Res. 2007; 19: 486-491
        • Werlinger K.
        • King T.K.
        • Clark M.M.
        • Pera V.
        • Wincze J.P.
        Perceived changes in sexual functioning and body image following weight loss in an obese female population: A pilot study.
        J Sex Marital Ther. 1997; 23: 74-78
        • Esposito K.
        • Giugliano F.
        • Di Palo C.
        • Giugliano G.
        • Marfella R.
        • D'Andrea F.
        • D'Armiento M.
        • Giugliano D.
        Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial.
        JAMA. 2004; 291: 2978-2984
        • Kim K.K.
        • Kang H.C.
        • Kim S.S.
        • Youn B.B.
        Influence of weight reduction by sibutramine on female sexual function.
        Int J Obes (2005). 2006; 30: 758-763
        • Esposito K.
        • Marfella R.
        • Ciotola M.
        • Di Palo C.
        • Giugliano F.
        • Giugliano G.
        • D'Armiento M.
        • D'Andrea F.
        • Giugliano D.
        Effect of a mediterranean‐style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial.
        JAMA. 2004; 292: 1440-1446
        • Esposito K.
        • Ciotola M.
        • Giugliano F.
        • De Sio M.
        • Giugliano G.
        • D'armiento M.
        • Giugliano D.
        Mediterranean diet improves erectile function in subjects with the metabolic syndrome.
        Int J Impot Res. 2006; 18: 405-410
        • Jensterle M.
        • Sebestjen M.
        • Janez A.
        • Prezelj J.
        • Kocjan T.
        • Keber I.
        • Pfeifer M.
        Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
        Eur J Endocrinol. 2008; 159: 399-406
        • Tarkun I.
        • Cetinarslan B.
        • Turemen E.
        • Sahin T.
        • Canturk Z.
        • Komsuoglu B.
        Effect of rosiglitazone on insulin resistance, C‐reactive protein and endothelial function in non‐obese young women with polycystic ovary syndrome.
        Eur J Endocrinol. 2005; 153: 115-121
        • Lord J.M.
        • Norman R.J.
        Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome.
        Cochrane Database Syst Rev. 2003
        • Pillai A.
        • Bang H.
        • Green C.
        Metformin and glitazones: Do they really help PCOS patients?.
        J Fam Pract. 2007; 56: 444-453
        • Kim Y.W.
        • Park S.Y.
        • Kim J.Y.
        • Huh J.Y.
        • Jeon W.S.
        • Yoon C.J.
        • Yun S.S.
        • Moon K.H.
        Metformin restores the penile expression of nitric oxide synthase in high‐fat‐fed obese rats.
        J Androl. 2007; 28: 555-560
        • Libeton M.
        • Dixon J.B.
        • Laurie C.
        • O'Brien P.E.
        Patient motivation for bariatric surgery: Characteristics and impact on outcomes.
        Obes Surg. 2004; 14: 392-398
        • American Society for Metabolic & Bariatric Surgery
        Rationale for the surgical treatment of morbid obesity.
        (accessed June 19, 2009)
        • Merhi Z.O.
        Bariatric surgery and subsequent sexual function.
        Fertil Steril. 2007; 87: 710-711
        • Camps M.A.
        • Zervos E.
        • Goode S.
        • Rosemurgy A.S.
        Impact of Bariatric surgery on body image perception and sexuality in morbidly obese patients and their partners.
        Obes Surg. 1996; 6: 356-360
        • Hafner R.J.
        • Watts J.M.
        • Rogers J.
        Quality of life after gastric bypass for morbid obesity.
        Int J Obes. 1991; 15: 555-560
        • Dallal R.M.
        • Smith J.A.
        • O'Leary M.P.
        • Harkaway R.C.
        • Sawh S.L.
        Profound sexual dysfunction is common in the morbidly obese male and is reversed after gastric bypass surgery.
        J Urol Suppl. 2008; 179: 405
        • Di Frega A.S.
        • Dale B.
        • Di Matteo L.
        • Wilding M.
        Secondary male factor infertility after Roux‐en‐Y gastric bypass for morbid obesity: Case report.
        Hum Reprod. 2005; 20: 997-998
        • Vazquez C.
        • Morejon E.
        • Munoz C.
        • López Y.
        • Balsa J.
        • Koning M.A.
        • Maldonado A.
        • García G.
        • Peromingo R.
        • Fresneda V.
        [Nutritional effect of bariatric surgery with Scopinaro operation. Analysis of 40 cases].
        Nutr Hosp. 2003; 18: 189-193
        • Khedun S.M.
        • Naicker T.
        • Maharaj B.
        Zinc, hydrochlorothiazide and sexual dysfunction.
        Cent Afr J Med. 1995; 41: 312-315